Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA. Ercan D, et al. Among authors: maertens o. Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7. Cancer Discov. 2012. PMID: 22961667 Free PMC article.
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Montero J, et al. Among authors: maertens o. Cell. 2015 Feb 26;160(5):977-989. doi: 10.1016/j.cell.2015.01.042. Cell. 2015. PMID: 25723171 Free PMC article.
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas.
Maertens O, Kuzmickas R, Manchester HE, Emerson CE, Gavin AG, Guild CJ, Wong TC, De Raedt T, Bowman-Colin C, Hatchi E, Garraway LA, Flaherty KT, Pathania S, Elledge SJ, Cichowski K. Maertens O, et al. Cancer Discov. 2019 Apr;9(4):526-545. doi: 10.1158/2159-8290.CD-18-0879. Epub 2019 Feb 1. Cancer Discov. 2019. PMID: 30709805 Free PMC article.
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers.
Guerra SL, Maertens O, Kuzmickas R, De Raedt T, Adeyemi RO, Guild CJ, Guillemette S, Redig AJ, Chambers ES, Xu M, Tiv H, Santagata S, Jänne PA, Elledge SJ, Cichowski K. Guerra SL, et al. Among authors: maertens o. Cancer Cell. 2020 May 11;37(5):705-719.e6. doi: 10.1016/j.ccell.2020.03.004. Epub 2020 Apr 2. Cancer Cell. 2020. PMID: 32243838 Free PMC article.
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.
De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K. De Raedt T, et al. Among authors: maertens o. Cancer Cell. 2011 Sep 13;20(3):400-13. doi: 10.1016/j.ccr.2011.08.014. Cancer Cell. 2011. PMID: 21907929 Free PMC article.
Elucidating distinct roles for NF1 in melanomagenesis.
Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Maertens O, et al. Cancer Discov. 2013 Mar;3(3):338-49. doi: 10.1158/2159-8290.CD-12-0313. Epub 2012 Nov 21. Cancer Discov. 2013. PMID: 23171796 Free PMC article.
mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.
Malone CF, Emerson C, Ingraham R, Barbosa W, Guerra S, Yoon H, Liu LL, Michor F, Haigis M, Macleod KF, Maertens O, Cichowski K. Malone CF, et al. Among authors: maertens o. Cancer Discov. 2017 Dec;7(12):1450-1463. doi: 10.1158/2159-8290.CD-17-0177. Epub 2017 Sep 29. Cancer Discov. 2017. PMID: 28963352 Free PMC article.
28 results